<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1336">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02428595</url>
  </required_header>
  <id_info>
    <org_study_id>CA005</org_study_id>
    <nct_id>NCT02428595</nct_id>
  </id_info>
  <brief_title>A Clinical Evaluation of the Eclipse™ System, a Vaginal Bowel Control (VBC) Therapy for Fecal Incontinence in Women</brief_title>
  <acronym>LIBERATE</acronym>
  <official_title>A Clinical Evaluation of the Eclipse™ System, a Vaginal Bowel Control (VBC) Therapy for Fecal Incontinence in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pelvalon, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pelvalon, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multi-center, prospective, within-subject control, open label clinical trial to evaluate the
      durability of the safety and effectiveness of the Eclipse™ System after 3 and 12 months of
      use.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Anticipated">May 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Proportion of treatment Responders in the Intent to Treat (ITT) cohort</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>% reduction in the average number of FI episodes per week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of treatment responders in the Per Protocol (PP) population</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>% reduction in the average number of FI episodes per week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean scores on subject-reported outcomes related to symptom severity</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>St. Mark's (Vaizey) Incontinence Severity Score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Improvement (PGI-I) scores</measure>
    <time_frame>3, 6, 9 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean scores on subject-reported outcomes related to QoL</measure>
    <time_frame>3, 6 and 12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Fecal Incontinence QoL (FIQoL)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Endpoint</measure>
    <time_frame>3, 6, 9 and 12 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of device-related adverse events, and device-related serious adverse events</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Fecal Incontinence</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eclipse™ System</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Eclipse™ System</intervention_name>
    <description>The Eclipse System is a vaginal bowel control (VBC) therapy intended to provide bowel control for women with fecal incontinence. It is comprised of a non-surgical device placed in the vagina (referred to as the &quot;Eclipse Insert&quot;) and a pressure-regulated pump which is used to inflate and deflate the Insert. A Sizing Kit, for use during the fitting process, and an evaluation Insert (referred to as the Trial Insert) are also part of the Eclipse System.</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Vaginal Bowel Control (VBC) Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Abbreviated Inclusion Criteria:

          -  History of FI for at least 6 months

          -  Subject willing and able to give written informed consent to participate in the study

          -  Subject can read, write and communicate fluently in English

          -  Subject willing and able to comply with visit schedule

          -  Subject is able to physically manage the insertion and removal of the Insert

        Abbreviated Exclusion Criteria:

          -  Vaginal childbirth within the last 18 months

          -  Currently pregnant or planning pregnancy during the study period

          -  Acute infections or genito-urinary injuries that would impact comfortable device use

          -  Current treatment for FI other than medical management

          -  Removal or diversion of any portion of the bowel

          -  Recent urogenital or colorectal surgeries

          -  Chronic abdominal pain in absence of diarrhea

          -  Chronic (&gt;6 mos) rectal, anal or pelvic pain

          -  Chronic watery diarrhea, unmanageable by drugs or diet

          -  Inflammatory Bowel Disease (IBD) such as Chron's or Ulcerative Colitis

          -  Rectal prolapse (mucosal or full thickness)

          -  Grade III or IV hemorrhoids

          -  Pelvic organ prolapse beyond the plane of the hymen

          -  Concurrent use of intra-vaginal pessary or other device

          -  Anal or pelvic malignancy within last 5 years

          -  History of pelvic irradiation for cancer

          -  Other significant medical or lifestyle factors that could confound the interpretation
             of the primary endpoint or increase subject risk
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Holly Richter, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cindy Jahans, BSc</last_name>
    <phone>650-276-0130</phone>
    <email>Cindy@pelvalon.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alison Moe, BSc</last_name>
    <phone>650-276-0130</phone>
    <email>Alison@pelvalon.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Howell, BSN, CCRC</last_name>
      <phone>205-975-8592</phone>
      <email>ahowell@uabmc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Robin Willingham, BSN</last_name>
      <phone>205-934-3904</phone>
      <email>rwillingham@uabmc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Holly Richter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital (MGH)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lieba Savitt, NP</last_name>
      <phone>617-643-5580</phone>
      <email>MGHpelvicfloorcenter@partners.org</email>
    </contact>
    <contact_backup>
      <last_name>Holly Milch, NP</last_name>
      <phone>617-643-5580</phone>
      <email>MGHpelvicfloorcenter@partners.org</email>
    </contact_backup>
    <investigator>
      <last_name>Liliana Bordeianou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Pagnillo, RN</last_name>
      <phone>973-971-7426</phone>
      <email>Jennifer.Pagnillo@atlantichealth.org</email>
    </contact>
    <investigator>
      <last_name>Patrick Culligan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Risela Nava</last_name>
      <phone>505-967-8428</phone>
      <email>hsc-urogyn-research@salud.unm.edu</email>
    </contact>
    <contact_backup>
      <last_name>Karen Box</last_name>
      <phone>505-967-8428</phone>
      <email>hsc-urogyn-research@salud.unm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gena Dunivan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betty Rupp, MPH</last_name>
      <phone>919-843-8114</phone>
      <email>brupp@med.unc.edu</email>
    </contact>
    <investigator>
      <last_name>Jennifer Wu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marsha Zartman, BSN, CCRC</last_name>
      <phone>513-463-2509</phone>
      <email>marsha.zartman@thechristhospital.com</email>
    </contact>
    <contact_backup>
      <last_name>Sharon Lamping, MA, CRC</last_name>
      <phone>513-585-2166</phone>
      <email>sharon.lamping@thechristhospital.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ian Paquette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Trynisha Cheadle, RN</last_name>
      <phone>405-271-8001</phone>
      <phone_ext>46205</phone_ext>
      <email>trynisha-cheadle@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Dena O'Leary, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorraine Flick</last_name>
      <phone>215-615-6569</phone>
      <email>lorraine.flick@uphs.upenn.edu</email>
    </contact>
    <contact_backup>
      <last_name>Michelle Kinglee</last_name>
      <phone>215-615-6569</phone>
      <email>michelle.kinglee@uphs.upenn.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Uduok Andy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Brown University (WIHRI)</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Spearin, BSc</last_name>
      <phone>401-274-1122</phone>
      <phone_ext>48226</phone_ext>
      <email>espearin@wihri.org</email>
    </contact>
    <contact_backup>
      <last_name>Ann Meers, RN</last_name>
      <phone>401-274-1122</phone>
      <phone_ext>48228</phone_ext>
      <email>ameers@wihri.org</email>
    </contact_backup>
    <investigator>
      <last_name>Charles Rardin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Sacred Heart</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Milton, MS, CCRC</last_name>
      <phone>509-474-4323</phone>
      <email>joan.e.milton@providence.org</email>
    </contact>
    <investigator>
      <last_name>Shane McNevin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robin Wasielewski, CCRC</last_name>
      <phone>608-417-4230</phone>
      <email>rwasielewsk2@wisc.edu</email>
    </contact>
    <investigator>
      <last_name>Heidi Brown, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://journals.lww.com/greenjournal/Citation/2015/03000/A_Vaginal_Bowel_Control_System_for_the_Treatment.3.aspx</url>
    <description>A Vaginal Bowel-Control System for the Treatment of Fecal Incontinence (results of the LIFE Study)</description>
  </link>
  <reference>
    <citation>Richter HE, Matthews CA, Muir T, Takase-Sanchez MM, Hale DS, Van Drie D, Varma MG. A vaginal bowel-control system for the treatment of fecal incontinence. Obstet Gynecol. 2015 Mar;125(3):540-7. doi: 10.1097/AOG.0000000000000639.</citation>
    <PMID>25730213</PMID>
  </reference>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 9, 2015</lastchanged_date>
  <firstreceived_date>April 18, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fecal Incontinence</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
